HCPLive

Hearing Loss Linked to Cognitive Impairment in Elderly Patients

 
MONDAY, Jan. 21 (HealthDay News) -- For older adults, hearing loss is independently associated with incident cognitive impairment; and about 11 percent of those aged 80 or older have dual sensory impairment (DSI), according to two studies published online Jan. 21 in JAMA Internal Medicine.

Frank R. Lin, M.D., Ph.D., from the Johns Hopkins School of Medicine in Baltimore, and colleagues examined whether hearing loss is independently correlated with accelerated cognitive decline among 1,984 older adults without prevalent cognitive impairment at baseline. The researchers found that, compared to those with normal hearing, among the 1,162 individuals with baseline hearing loss, the annual rates of cognitive decline were 41 percent greater on the Modified Mini-Mental State Examination score and 32 percent greater on the Digit Symbol Substitution test scores. Compared to those with normal hearing, individuals with hearing loss at baseline had a significantly increased risk (24 percent greater) for incident cognitive impairment.

Bonnielin K. Swenor, M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues examined the prevalence of DSI in hearing and vision using data from the 1999 to 2006 cycles of the National Health and Nutritional Examination Survey. The researchers found that approximately 1.5 million Americans aged 20 years and older had DSI. The prevalence of DSI was less than 1 percent for individuals younger than 70 years and was 11.3 percent for those aged 80 or older. Only 19 percent of those aged 80 or older were free of any sensory impairment.

"Concurrent vision impairment could potentially accelerate the rate of cognitive decline and dementia previously reported in individuals with hearing impairment alone," Swenor and colleagues conclude.

An author associated with both studies disclosed financial ties to Pfizer and Cochlear Europe.
 

Abstract - Lin
Full Text (subscription or payment may be required)
 
Abstract - Swenor
Full Text (subscription or payment may be required)
 
Editorial (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vAR$